论文部分内容阅读
１９９５年７月～１９９７年１２月，用含泰素的联合化疗方案治疗了阿霉素抗药的晚期乳腺癌２０例，其中ＥＴＰ方案治疗１２例，ＴＩＭ方案治疗４例，ＴＥ方案治疗２例，ＣＴＦ方案、ＴＩ方案治疗各１例。全组化疗共７４周期，中位周期数３．５周期（２～６周期）。结果，ＣＲ４例，ＰＲ１０例，ＭＲ２例，ＳＤ１例，ＰＤ３例，总有效率（ＣＲ＋ＰＲ）７０％。全组中位缓解期７个月（２～１３个月）。主要剂量限制毒性为骨髓抑制，以白细胞减少为主，Ⅲ度～Ⅳ度白细胞减少发生率为４３％。与泰素相关的常见不良反应为脱发、肌肉／关节痛和周围神经痛，发生率分别为１００％、８０％和４０％，均为轻、中度，停药后可恢复。我们认为含泰素的联合化疗对阿霉素耐药的转移性乳腺癌有很好的疗效，可以考虑作为第二线治疗方案
From July 1995 to December 1997, 20 patients with adriamycin-resistant advanced breast cancer were treated with a combination chemotherapy regimen containing Taxol, including 12 patients with ETP regimen, 4 patients with TIM regimen, and 2 patients with TE regimen. , CTF program, TI program treatment in 1 case. A total of 74 cycles of chemotherapy were performed in the whole group, with a median cycle of 3.5 cycles (2 to 6 cycles). As a result, there were 4 cases of CR, 10 cases of PR, 2 cases of MR, 1 case of SD, 3 cases of PD, and a total effective rate (CR+PR) of 70%. The median remission period of the whole group was 7 months (2 to 13 months). The main dose-limiting toxicity was myelosuppression, with neutropenia predominant, with a neutropenia of grade III-IV of 43%. The common adverse reactions associated with Taxol were hair loss, muscle/joint pain, and peripheral neuralgia. The incidences were 100%, 80%, and 40%, respectively. Both were mild to moderate and could be recovered after drug withdrawal. We believe that combination therapy with paclitaxel has a good effect on adriamycin-resistant metastatic breast cancer and can be considered as a second-line treatment option